IASLC分期和预后因素委员会(The IASLC Staging and Prognostic Factors Committee,SPFC)
The IASLC Lung Cancer Staging Project: A Renewed Call to Participation ( PDF阅读/下载 )
网站内容发布:
Table 1. Study Objectives
Component | Objective |
T | a)Assess the prognostic impact of tumor size b)Assess the classification capacity of each descriptor defining T status c)Study new conditions not included in the present T (e.g., differences between parietal pleura invasion and rib invasion) |
N | a)Assess the prognostic impact of N status b)Assess the prognostic impact of i.Nodal extent (single vs. multiple station involvement in N1 and N2 locations) ii.Number of involved lymph nodes iii.Lymph node ratio (i.e., number of involved lymph nodes divided by the number of removed lymph nodes) iv.Nodal size (i.e., largest involved node within the relevant N category) v.Individual nodes involved in each nodal category c)Assess the prognostic impact of extracapsular extension d)Assess the prognostic impact of the N3 nodal location (i.e., contralateral mediastinum and ipsilateral or contralateral supraclavicular fossa) |
M | a)Assess the prognostic impact of M status b)Assess the prognostic impact of i.Single metastasis in a single organ ii.Multiple metastases in a single organ iii.Multiple metastases in several organs |
Other | a)Assess the prognostic impact of histologic type and grade b)Assess the reliability of staging methods utilized in clinical staging (for those tumors with pretreatment and postsurgical classification) c)Assess the prognostic impact of complete, incomplete, and uncertain resections according to the proposed definitions of the International Association for the Study of Lung Cancer d)Assess the prognostic impact of clinical factors, including comorbidity and pulmonary function tests e)Assess the prognostic impact of maximum standard uptake value (SUVmax) at the primary site and in any positive nodal sites for those patients with positron emission tomography scans in the pretreatment staging |
Prognostic groups | a)Assess the prognostic relevance of individual molecular parameters b)Create prognostic groups based on the combination of anatomic and nonanatomic parameters, including molecular markers, clinical and epidemiological features, and other parameters, such as lung function tests, blood analyses and SUVmax |
SUVmax, maximum standardized uptake value.
Table 2. Time Line
Year: | 2018-2019 | 2020-2021 | 2022 | 2023 | 2024 |
Activity: | EDC case registration (retrospective to 2011) | Follow-up and preliminary analysis | Final data analysis | Publication of recommendations in the Journal of Thoracic Oncology
Submission of recommendations to the UICC and AJCC | Publication of the ninth edition of the TNM classification by the UICC and AJCC |
EDC, electronic data capture; UICC, Union for International Cancer Control; AJCC, American Joint Committee on Cancer.